Lv1
84 积分 2025-10-15 加入
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
5天前
已关闭
Enzymes in Addressing Hypoxia for Biomaterials Engineering
9天前
已完结
Targeted ROS Scavenging for Disease Therapies Using Nanomaterials
9天前
已完结
Enzymes in Addressing Hypoxia for Biomaterials Engineering
13天前
已完结
Catalytic Nanozyme for Radiation Protection
13天前
已完结
Engineering Nonpathogenic Bacteria for Synergistic Tumor-Targeted Protein Degradation and Immunotherapy by Checkpoint-Inhibiting Nanobodies
2个月前
已完结
Biomimetic Copper Nanozyme Reprograms Cold Tumor via Cuproptosis–Pyroptosis Crosstalk for Potent Renal Carcinoma Immunotherapy
4个月前
已完结
Biomimetic Copper Nanozyme Reprograms Cold Tumor via Cuproptosis–Pyroptosis Crosstalk for Potent Renal Carcinoma Immunotherapy
4个月前
已完结
Engineering a Bifunctional Smart Nanoplatform Integrating Nanozyme Activity and Self-Assembly for Kidney Cancer Diagnosis and Classification
4个月前
已完结
Mycobacterium bovis bacille Calmette–Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy
4个月前
已完结
皖公网安备34019202002308
